18F-PSMA 1007 Uptake in Brain Metastases From Breast Cancer

Fahad Marafi 1, Arun Sasikumar 2, Mahmoud Alfeeli 1, Wael Fathallah 3

Affiliations

01 February 2020

-

doi: 10.1097/RLU.0000000000002821

Abstract

A 64-year-old woman with metastatic breast cancer on follow-up had suspicious recurrent brain metastases. She underwent F-FDG PET/CT, F-PSMA 1007 brain PET/CT, and brain MRI. F-PSMA 1007 showed intense tracer localization in the suspected recurrent brain metastasis in right parietal lobe and also picked up 2 more metastatic brain lesions, which had concurrent findings of metastasis in subsequent MRI. Our case highlights the feasibility of F-PSMA 1007 PET/CT imaging of brain metastases from nonprostate cancers. It may be used as surrogate imaging tracer for potential theranostic application using alpha or beta emitters considering its similarity to PSMA-617.

Similar articles

18F-PSMA 1007 Brain PET/CT Imaging in Glioma Recurrence.

Marafi F, Sasikumar A, Fathallah W, Esmail A.Clin Nucl Med. 2020 Jan;45(1):e61-e62. doi: 10.1097/RLU.0000000000002668.PMID: 31162269

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.PMID: 30843003

18F-PSMA 1007 Uptake in a Man With Metastatic Breast Cancer.

Marafi F, Sasikumar A, Alfeeli M, Thuruthel S.Clin Nucl Med. 2020 Jun;45(6):e276-e278. doi: 10.1097/RLU.0000000000003013.PMID: 32332302

18F-PSMA-1007 Uptake in Pulmonary Lymphangitic Carcinomatosis Metastasis From Prostate Cancer.

Liu BL, Hong JJ, Tang K, Lin J, Zheng XW.Clin Nucl Med. 2021 Jul 1;46(7):e355-e357. doi: 10.1097/RLU.0000000000003582.PMID: 33782286

Utility of 68 Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma.

Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman MS.J Med Imaging Radiat Oncol. 2017 Jun;61(3):372-378. doi: 10.1111/1754-9485.12590. Epub 2017 Jan 24.PMID: 28116853 Review.

Cited by

Prostate-Specific Membrane Antigen as Target for Neuroimaging of Central Nervous System Tumors.

Stopa BM, Crowley J, Juhász C, Rogers CM, Witcher MR, Kiser JW.Mol Imaging. 2022 Apr 15;2022:5358545. doi: 10.1155/2022/5358545. eCollection 2022.PMID: 35517711 Free PMC article. Review.

Current landscape and future perspectives in preclinical MR and PET imaging of brain metastasis.

Aasen SN, Espedal H, Keunen O, Adamsen TCH, Bjerkvig R, Thorsen F.Neurooncol Adv. 2021 Oct 14;3(1):vdab151. doi: 10.1093/noajnl/vdab151. eCollection 2021 Jan-Dec.PMID: 34988446 Free PMC article. Review.

Non-prostate uptake on 18F-PSMA-1007 PET/CT: a case of myeloma.

Veerasuri S, Redman S, Graham R, Meehan C, Little D.BJR Case Rep. 2020 Nov 3;7(2):20200102. doi: 10.1259/bjrcr.20200102. eCollection 2021 Apr 1.PMID: 33841899 Free PMC article.

Duodenal Adenocarcinoma Mimicking Metastasis of Prostate Cancer on 18F-Prostate-Specific Membrane Antigen-1007 PET/CT.

Soeda F, Watabe T, Kato H, Uemura M, Nonomura N.Clin Nucl Med. 2021 Jan;46(1):49-51. doi: 10.1097/RLU.0000000000003400.PMID: 33208620 Free PMC article.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Freitag MT, Kesch C, Cardinale J, et al. Simultaneous whole-body (18)F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2018;45:340–347.
  2.  
    1. Giesel FL, Hadaschik B, Cardinale J, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678–688.
  3.  
    1. Giesel FL, Will L, Kesch C, et al. Biochemical recurrence of prostate cancer: initial results with [(18)F]PSMA-1007 PET/CT. J Nucl Med. 2018;59:632–635.
  4.  
    1. Kesch C, Vinsensia M, Radtke JP, et al. Intraindividual comparison of (18)F-PSMA-1007 PET/CT, multiparametric MRI, and radical prostatectomy specimens in patients with primary prostate cancer: a retrospective, proof-of-concept study. J Nucl Med. 2017;58:1805–1810.
  5.  
    1. Seifert R, Schafigh D, Bogemann M, et al. Detection of local relapse of prostate cancer with 18F-PSMA-1007. Clin Nucl Med. 2019;44:e394–e395.
  6.  
    1. Pianou NK, Stavrou PZ, Vlontzou E, et al. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT. Hell J Nucl Med. 2019;22:6–9.
  7.  
    1. Giesel FL, Cardinale J, Schafer M, et al. (18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. Eur J Nucl Med Mol Imaging. 2016;43:1929–1930.
  8.  
    1. Sasikumar A, Joy A, Pillai MR, et al. Diagnostic value of 68Ga PSMA-11 PET/CT imaging of brain tumors-preliminary analysis. Clin Nucl Med. 2017;42:e41–e48.
  9.  
    1. Sasikumar A, Kashyap R, Joy A, et al. Utility of 68Ga-PSMA-11 PET/CT in imaging of glioma—a pilot study. Clin Nucl Med. 2018;43:e304–e309.
  10.  
    1. Chakraborty PS, Kumar R, Tripathi M, et al. Detection of brain metastasis with 68Ga-labeled PSMA ligand PET/CT: a novel radiotracer for imaging of prostate carcinoma. Clin Nucl Med. 2015;40:328–329.
  11.  
    1. Chan M, Hsiao E, Turner J. Cerebellar metastases from prostate cancer on 68Ga-PSMA PET/CT. Clin Nucl Med. 2017;42:193–194.
  12.  
    1. Kasoha M, Unger C, Solomayer EF, et al. Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases. Clin Exp Metastasis. 2017;34:479–490.
  13.  
    1. Sathekge M, Lengana T, Modiselle M, et al. (68)Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. Eur J Nucl Med Mol Imaging. 2017;44:689–694.

Page Navigation